Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $58.41 Consensus PT from Brokerages

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have been given a consensus rating of “Moderate Buy” by the eighteen research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, fourteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $58.4118.

Several equities analysts recently commented on the stock. Truist Financial raised shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, March 25th. Wall Street Zen raised shares of Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Wells Fargo & Company boosted their price target on shares of Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Wedbush decreased their price target on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Finally, Guggenheim lowered their price objective on Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, May 8th.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE opened at $29.28 on Monday. The company has a market cap of $2.88 billion, a P/E ratio of -4.79 and a beta of 0.31. Ultragenyx Pharmaceutical has a 52 week low of $18.29 and a 52 week high of $39.89. The business has a 50-day simple moving average of $27.28 and a two-hundred day simple moving average of $24.49.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The company had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.19 million. During the same quarter in the prior year, the company earned ($1.57) earnings per share. The company’s quarterly revenue was down 2.2% on a year-over-year basis. Equities research analysts anticipate that Ultragenyx Pharmaceutical will post -4.53 EPS for the current year.

Insiders Place Their Bets

In other news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $25.05, for a total transaction of $50,100.00. Following the completion of the sale, the director owned 21,095 shares in the company, valued at approximately $528,429.75. This trade represents a 8.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Shehnaaz Suliman sold 5,740 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $25.12, for a total value of $144,188.80. Following the transaction, the director directly owned 27,951 shares of the company’s stock, valued at $702,129.12. The trade was a 17.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 19,319 shares of company stock valued at $476,837 in the last ninety days. Corporate insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RARE. CANADA LIFE ASSURANCE Co lifted its position in Ultragenyx Pharmaceutical by 2.0% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 26,932 shares of the biopharmaceutical company’s stock valued at $817,000 after acquiring an additional 534 shares in the last quarter. Van ECK Associates Corp increased its holdings in shares of Ultragenyx Pharmaceutical by 26.1% in the 3rd quarter. Van ECK Associates Corp now owns 2,650 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 549 shares in the last quarter. Tidal Investments LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 4.7% in the 2nd quarter. Tidal Investments LLC now owns 12,591 shares of the biopharmaceutical company’s stock worth $458,000 after purchasing an additional 564 shares in the last quarter. Rafferty Asset Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 0.4% in the fourth quarter. Rafferty Asset Management LLC now owns 157,061 shares of the biopharmaceutical company’s stock worth $3,612,000 after purchasing an additional 577 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 43.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,489 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 751 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.